

Chronic lymphocytic leukemia (CLL): Update Bulletin #2

<https://marketpublishers.com/r/C3EA0C89525EN.html>

Date: January 2018

Pages: 0

Price: US\$ 1,095.00 (Single User License)

ID: C3EA0C89525EN

Abstracts

This edition presents key opinion leader (KOL) views on recent developments in the chronic lymphocytic leukaemia (CLL) market. Topics covered include: full results from the Phase III study of AbbVie/Roche's Venclexta/Venclyxto (venetoclax) in combination with Rituxan/MabThera (rituximab; Roche) presented at the ASH meeting in December 2017; the initiation of a Phase III study investigating BeiGene's novel Bruton's tyrosine kinase (BTK) inhibitor zanubrutinib (BGB-3111) in patients with relapsed/refractory CLL; Phase I/II results for Juno Therapeutics/Celgene's JCAR014; and pilot trial results for an anti-CD19 CAR-T cell therapy in combination with Imbruvica (ibrutinib; Janssen Biotech/AbbVie) in patients with high-risk CLL.

Business Questions:

In light of the positive results for Venclexta/Rituxan in the MURANO study, do KOLs envisage any changes to the second-line treatment regimen for CLL?

Do KOLs think it will be possible to overcome the side effects associated with the use of Venclexta/Rituxan?

If Venclexta/Rituxan is approved for treating patients with relapsed/refractory CLL, how widespread will its use become and why?

Will zanubrutinib's selectivity for BTK inhibition translate into a clinically meaningful benefit for patients with CLL?

What role will zanubrutinib play within the CLL setting, if approved, and how well will it compete with other BTK inhibitors?

Will the toxicity associated with the use of anti-CD19 CAR-T cells confine their role to one of salvage therapy for CLL?

Do KOLs think that combining anti-CD19 CAR-T cells with Imbruvica will provide any therapeutic advantages for patients with CLL?

Apart from CD19, are there any other molecules which can be identified by KOLs as potentially effective therapeutic targets for CAR-T cell therapy?

I would like to order

Product name: Chronic lymphocytic leukemia (CLL): Update Bulletin #2

Product link: <https://marketpublishers.com/r/C3EA0C89525EN.html>

Price: US\$ 1,095.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C3EA0C89525EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970